SCHEMBL23913065

SCHEMBL23913065

C/N=C/c1cncc(-c2c(OCc3ccc(Cl)cc3)ccc(-c3cc(C(F)(F)F)n(C)n3)c2O)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
TBXA2R P21731 4/20 0.33
PTGER1 P34995 4/20 0.33
MAPT P10636 4/20 0.32
MITF O75030 2/20 0.32
POLB P06746 2/20 0.32
UBE2N P61088 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22825444 0.91 PTGER1 (0.33) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL21786618 0.91 SMN1; SMN2 (0.38) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL21786493 0.87 PTGER1 (0.39) SMN1; SMN2KMT2AALDH1A1MEN1TBXA2R
SCHEMBL23913034 0.86 PTGDR2 (0.30)
SCHEMBL21786542 0.85 USP7 (0.35) TBXA2RPTGER1HTR2AHTR2CCCR5
SCHEMBL21786448 0.84 CYP11B1 (0.39) RAB9AKMT2AALDH1A1MEN1TBXA2R
SCHEMBL21786446 0.82 PTGER1 (0.40) SMN1; SMN2RAB9AKMT2APTGER1MAPT
SCHEMBL21786420 0.82 PTPN1 (0.40) SMN1; SMN2KMT2AALDH1A1MEN1PTGER1
SCHEMBL21786590 0.82 NPSR1 (0.36) SMN1; SMN2KMT2AALDH1A1MEN1PTGER1
SCHEMBL23913056 0.81 TBXA2R (0.35) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents NORTHWESTERN UNIVERSITY (US) 2021-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents MYC, MYCBP, MYCBP2 SMN1; SMN2 4195/4885RAB9A 2795/4885NPC1 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.